Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NeuroDerm Ltd NDRM

Healthcare Biotechnology
"NeuroDerm Ltd is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system diseases, including Parkinson's disease as well as other CNS diseases."

Recent & Breaking News (NDAQ:NDRM)

NeuroDerm Ltd. Announces Pricing of Public Offering

GlobeNewswire July 15, 2015

NeuroDerm Ltd. Files Registration Statement for Proposed Follow-On Offering

GlobeNewswire July 2, 2015

NeuroDerm Poster Selected for Blue Ribbon Highlights Session During 19th International Congress of Parkinson's Disease and Movement Disorders Annual Meeting

GlobeNewswire June 18, 2015

NeuroDerm Announces Start of a Pharmacokinetic, Head-To-Head Comparison Study of ND0612H and Duodopa(R)

GlobeNewswire June 11, 2015

NeuroDerm's Latest Clinical Data Accepted as Late Breaking News to the International Parkinson and Movement Disorder Society's 19th International Congress on June 14-18, 2015 in San Diego

GlobeNewswire June 9, 2015

NeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire June 2, 2015

NeuroDerm to Ring The Nasdaq Stock Market Opening Bell on June 3, 2015

GlobeNewswire June 2, 2015

NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update

GlobeNewswire May 27, 2015

NeuroDerm CEO to Present at Jefferies 2015 Healthcare Conference on June 1, 2015

GlobeNewswire May 26, 2015

NeuroDerm to Host First Quarter 2015 Financial Results Conference Call on May 27, 2015

GlobeNewswire May 20, 2015

NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease

GlobeNewswire May 8, 2015

NeuroDerm Files Annual Report on Form 20-F for the Year Ended December 31, 2014

GlobeNewswire April 29, 2015

GenSpera Looks Undervalued Compared to Its Peers

Accesswire April 27, 2015

NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update

GlobeNewswire April 2, 2015

NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease at the 67th Annual Meeting of the American Academy of Neurology

GlobeNewswire April 1, 2015

Technology Applications International Corporation (NUUU) and REJUVEL 3D Capitalize On New Cosmetics Retail Trends

Accesswire March 19, 2015

NeuroDerm CEO to Present at Upcoming Investor Conferences

GlobeNewswire February 24, 2015

NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy

GlobeNewswire January 19, 2015

NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease

GlobeNewswire December 30, 2014

NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update

GlobeNewswire December 18, 2014